Home > Cardiology > ACC 2021 > Heart Failure and Cardiomyopathy > Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF

Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF

Presented By
Prof. Douglas Mann, Washington School of Medicine, USA
Conference
ACC 2021
Trial
Phase 4, LIFE
Sacubitril/valsartan was not superior to valsartan at lowering N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure and reduced ejection fractions (HFrEF) in the phase 4 LIFE trial [1]. It also did not improve clinical outcomes or reduce the risk of death in these patients when compared with valsartan alone. There was a statistically significant higher risk of hyperkalaemia associated with sacubitril/valsartan. Sacubitril/valsartan is a first-in-class angiotensin receptor neprilysin inhibitor that demonstrated superior morbidity and mortality outcomes in patients with chronic HFrEF when compared with enalapril in the PARADIGM-HF trial [2]. However, very few (<1%) of the patients included in the PARADIGM-HF trial had advanced heart failure (defined as New York Heart Association [NYHA] class 4), and so evidence was lacking on the safety and efficacy of sacubitril/valsartan in this group of patients. The LIFE ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on